Japanese Pharmacopoeia, 19th Edition
Japan's official pharmacopoeia — the 19th Edition (JP 19), issued by MHLW ministerial notification and published on 10 April 2026 with immediate effect; the transitional period from the 18th Edition ends on 30 September 2027. It carries the legally binding standards for drugs on the Japanese market: monographs for substances and preparations, general tests and apparatus, and general notices — with an official English translation published free through the PMDA.
What this does not cover
stated in the document's own scope- Sets product and testing standards; manufacturing practice in Japan is governed by the GMP Ordinance (MHLW No. 179), a separate instrument administered by PMDA.
- Binding for the Japanese market; other markets apply their own compendia (USP, Ph. Eur., ChP), with only the PDG-harmonised texts aligned across them.
- Monograph coverage is not universal — articles without a JP monograph are controlled through their approved registered specifications rather than the compendium.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The Japanese Pharmacopoeia is Japan's official compendium of drug standards — the legally binding specifications for medicines on the Japanese market. The current edition is the 19th (JP 19), published on 10 April 2026 with immediate effect; the 18th Edition’s standards may still be applied until its transitional period ends on 30 September 2027. The compendium carries the General Notices that govern interpretation, general rules for preparations, the general tests, processes, and apparatus used for compendial testing, and the official monographs for drug substances and preparations. An official English edition is published free of charge through the PMDA, which makes the JP one of the most accessible of the major pharmacopoeias.
Scope & applicability
Drugs marketed in Japan: compliance with the JP is a legal requirement under the Pharmaceuticals and Medical Devices (PMD) Act for articles the pharmacopoeia covers. MHLW issues the pharmacopoeia; PMDA administers regulatory operations and hosts the English edition.
Legal basis & how it acquires force
Issued by the Ministry of Health, Labour and Welfare under the Pharmaceuticals and Medical Devices (PMD) Act, which gives JP standards legal force for the articles the pharmacopoeia lists. The ministry issues each edition and supplement by ministerial notification — the 19th Edition on 10 April 2026, as No. 220 did for the 18th in 2021 — while the PMDA administers day-to-day regulatory operations and hosts the official English translation. MHLW and PMDA are distinct: the ministry legislates and notifies; the agency administers.
Document structure
| Part | Covers |
|---|---|
| General Notices | The interpretive rules governing how monograph requirements and compendial tests apply |
| General Rules for Preparations | Requirements by dosage-form class for preparations |
| General Tests, Processes and Apparatus | The compendial test methods, reagents, and apparatus specifications |
| Official Monographs | Substance-by-substance and preparation-by-preparation specifications: identity, purity, assay, and tests |
| General Information | Supporting technical texts that inform, without themselves being mandatory standards |
Key requirements
- Articles listed in the JP meet their monograph specifications
- Testing per the JP general tests, processes, and apparatus, or validated equivalents where permitted
- Interpretation per the General Notices, which govern how monograph requirements apply
Implementation tips
- For global products, run JP alongside USP/Ph. Eur. in one specification matrix — pharmacopoeial-harmonisation (PDG) texts cover part of the ground, but JP-specific tests remain and must be met for Japan release
Revision notes
JP 19 published 10 April 2026 with immediate effect; until 30 September 2027 the 18th Edition standards (JP XVIII, Notification No. 220 of 2021, with Supplements I and II) may still be applied, after which only JP 19 applies. The JP participates in the Pharmacopoeial Discussion Group with USP and Ph. Eur.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The JP is one of the three pharmacopoeias of the Pharmacopoeial Discussion Group, working with the USP and the European Pharmacopoeia to harmonise excipient monographs and general chapters — so a subset of texts is aligned across the three, while JP-specific requirements remain. Japan's GMP layer is separate: manufacturing is governed by MHLW Ordinance No. 179 administered through PMDA inspection, with the JP supplying the product-standards layer, analogous to the USP's relationship with FDA CGMP.
JP 19: frequently asked questions
Quick answers to common questions about JP 19.
What is the current edition of the Japanese Pharmacopoeia?
The 19th Edition (JP 19), published by MHLW ministerial notification on 10 April 2026 with immediate effect. The 18th Edition’s standards may still be applied until the transitional period ends on 30 September 2027.
Who publishes the JP — MHLW or PMDA?
The Ministry of Health, Labour and Welfare issues the pharmacopoeia by ministerial notification; the PMDA administers regulatory operations and publishes the official English edition. The ministry is the issuing authority, the agency the administrator.
Is the Japanese Pharmacopoeia legally binding?
Yes. Under the PMD Act, drugs covered by JP monographs must comply with the compendial standards for the Japanese market — the same structural role the USP plays in the US and the Ph. Eur. in Europe.
Is the JP available in English?
Yes — an official English translation is published free through the PMDA website, which distinguishes the JP from compendia that are sold, and makes it directly usable in global specification matrices.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.